New York-based Forest Laboratories Inc. and Swiss drugmaker Glenmark Pharmaceuticals SA reported disappointing top-line results from a Phase IIb dose range-finding study of oglemilast in patients with chronic obstructive pulmonary disease (COPD). (BioWorld Today) Read More
